by B2i | Apr 30, 2020 | Press Releases
JUPITER, FL / April 30, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and...
by B2i | Mar 30, 2020 | Press Releases
New research license agreement with WuXi Biologics, a leading global CDMO Two new fully funded collaborations and one expanded collaboration signed in 2020, including the third fully funded collaboration with a top tier animal health company Six funded research...
by B2i | Mar 30, 2020 | Press Releases
JUPITER, FL / March 30, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development,...
by B2i | Mar 19, 2020 | Press Releases
NEW YORK, NY / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic’s Chief Financial Officer Ping Rawson will be presenting at this year’s New York City based Investor Summit on March 25th-26th. During the current climate of concern, The...
by B2i | Mar 18, 2020 | Press Releases
JUPITER, FL / March 18, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development,...
by B2i | Mar 16, 2020 | Press Releases
JUPITER, FL / March 16, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and...
